New Immuno-PET Tracer Outperforms FDG PET in Detecting PD-L1 in Head and Neck Cancers

A groundbreaking study has introduced a novel peptide-based PET tracer, ^18F-AlF-NOTA-PCP2, which shows superior ability to assess PD-L1 expression in patients with head and neck cancers compared to the traditional ^18F-FDG PET scan. PD-L1 is an important biomarker that can influence immunotherapy decisions, and accurately measuring its levels non-invasively remains a challenge due to the limitations of current methods.

This innovative tracer was developed with the aim of improving hydrophilicity and achieving higher tumor-to-background contrast, making it more effective for visualizing PD-L1 expression. Preclinical experiments in mice demonstrated that ^18F-AlF-NOTA-PCP2 binds specifically and with high affinity to PD-L1-positive tumors. In clinical settings, 24 patients with head and neck squamous cell carcinoma underwent PET/CT scans using this new tracer, with additional scans using the conventional FDG tracer in some cases. The results revealed a strong correlation between ^18F-AlF-NOTA-PCP2 uptake and PD-L1 levels confirmed via immunohistochemistry.

Compared to ^18F-FDG, which had only a moderate correlation, the new tracer provides a more precise, non-invasive approach to gauge PD-L1 expression. This advancement could significantly enhance patient selection for immunotherapy, allowing treatments to be better tailored to individual tumor biology. The study was presented at the SNMMI 2025 Annual Meeting, where the image comparing the two tracers was honored as the SNMMI Image of the Year.

PD-L1 expression is common in head and neck cancers, particularly in squamous cell carcinoma. Current assessment methods rely on biopsies, which may not fully represent tumor heterogeneity. The development of ^18F-AlF-NOTA-PCP2 addresses this gap by enabling real-time imaging of PD-L1 across the entire tumor landscape. According to researchers, this tracer offers high-yield production and ease of clinical translation, potentially paving the way for more accurate and personalized immunotherapy strategies.

Experts like Dr. Yong Wang and Dr. Heather Jacene emphasize that targeted molecular imaging with specific tracers like this could revolutionize how clinicians monitor and treat cancers. Pending regulatory approval, ^18F-AlF-NOTA-PCP2 could become a standard tool within two to three years, transforming the landscape of oncology imaging and patient management.